Viridian Therapeutics, Inc. VRDN Investments - Amortized Cost Basis
Investments - Amortized Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s investments - amortized cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s investments - amortized cost basis?
- Viridian Therapeutics, Inc. (VRDN) reported investments - amortized cost basis of $586.4M in Q1 2026.
- How has Viridian Therapeutics, Inc.'s investments - amortized cost basis changed year-over-year?
- Viridian Therapeutics, Inc.'s investments - amortized cost basis decreased by 6.6% year-over-year, from $627.85M to $586.4M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s investments - amortized cost basis?
- Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s investments - amortized cost basis has grown at a 35.4% compound annual growth rate (CAGR), from $197.02M to $661.82M.